Lowering bad cholesterol and increasing good cholesterol may reduce risk of gallstone formation

Written By :  Dr. Kamal Kant Kohli
Published On 2023-11-28 05:31 GMT   |   Update On 2023-11-28 06:37 GMT

Cholelithiasis is a prevalent hepatobiliary disorder that primarily affects Western populations. Since It is a significant risk factor for cholangiocarcinoma therefore it is important to understand factors influencing cholelithiasis for developing effective prevention and treatment strategies.A new study has shed light on the complex relationship between serum lipids, lipid-modifying...

Login or Register to read the full article

Cholelithiasis is a prevalent hepatobiliary disorder that primarily affects Western populations. Since It is a significant risk factor for cholangiocarcinoma therefore it is important to understand factors influencing cholelithiasis for developing effective prevention and treatment strategies.

A new study  has shed light on the complex relationship between serum lipids, lipid-modifying targets, and cholelithiasis, a common condition characterized by the formation of gallstones.

Researchers at the First Hospital of Jilin University have found in a new study that lowering bad cholesterol i.e  LDL-C and increasing good  cholesterol i.e HDL-C  is  associated with reduced risk of gallstone formation.The research employed a combination of observational and Mendelian randomization (MR) approaches to comprehensively assess these associations.

The study has been  published in the journal Gut. 

Previous research has explored the role of serum lipids and lipid-modifying targets in cholelithiasis development. However, findings have been inconsistent, highlighting the need for further investigation. The current study aimed to address this gap by conducting a comprehensive analysis of these relationships.

The study utilized data from the UK Biobank, a large-scale biobank resource, to examine the associations between serum lipids (total cholesterol, LDL-C, HDL-C, and triglycerides) and cholelithiasis risk. The researchers found that serum LDL-C and HDL-C levels were inversely associated with cholelithiasis risk, indicating that lower LDL-C and higher HDL-C levels were associated with a reduced risk of gallstone formation.

Interestingly, the relationship between serum total cholesterol and cholelithiasis was non-linear, with lower cholesterol levels associated with an increased risk of gallstones. This finding contrasts with conventional wisdom, which suggests that lower cholesterol levels are generally beneficial for health.

The researchers also employed MR, a genetic approach, to investigate the causal effects of serum lipids and lipid-modifying targets on cholelithiasis risk. MR utilizes genetic variants as proxies for specific risk factors, allowing for assessing causal relationships without the confounding effects of lifestyle and environmental factors.

MR analyses supported the observational findings, confirming that lower serum total cholesterol and higher triglyceride levels were independent causal risk factors for cholelithiasis.

The findings of this study provide valuable insights into the complex interplay between serum lipids, lipid-modifying targets, and cholelithiasis risk. The researchers suggest that these findings could inform the development of personalized risk assessment strategies and potential therapeutic interventions for cholelithiasis prevention.

Further research is warranted to elucidate the underlying mechanisms behind the observed associations and identify specific lipid-modifying targets that may hold promise for preventing or treating cholelithiasis.

Reference:

Chen L, Qiu W, Sun X, et alNovel insights into causal effectsGut of serum lipids and lipid-modifying targets on cholelithiasisGut Published Online First: 09 November 2023. doi: 10.1136/gutjnl-2023-330784.

Tags:    
Article Source : Gut

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News